Hangzhou, China, Oct. 14, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a China-based supplier of medical devices operating through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd., and its Chinese affiliates, today announced the receipt of a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”). The Letter informs the Company of Nasdaq’s decision to delist its Class A ordinary shares from The Nasdaq Capital Market. This action was prompted by the Company’s Class A ordinary shares having a closing bid price of $0.10 or less for ten consecutive trading days, concluding on October 8, 2025, a condition that triggers a notice of delisting under Nasdaq Listing Rule 5810(c)(3)(A)(iii).
As stipulated in the Letter, unless the Company submits an appeal request, trading of its Class A ordinary shares will be suspended at the commencement of business on October 20, 2025. Subsequently, a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to initiate the removal of the Company’s securities from listing and registration on Nasdaq.
The Company retains the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to contest this determination, with the deadline for such a request being October 16, 2025. Submitting a hearing request will temporarily halt the suspension of the Company’s securities while the Panel’s decision is pending. WORK Medical intends to appeal the determination to the Panel on or before October 16, 2025.
The Company plans to evaluate all available courses of action to re-establish compliance with the Nasdaq Listing Rules for continued listing, potentially including, if deemed appropriate, the implementation of a reverse share split.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, operating via its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its related entities in China, functions as a supplier of medical devices. The Company is engaged in the development and manufacturing of Class I and II medical devices and distributes Class I and II disposable medical devices through its operating subsidiaries within China. Its extensive product portfolio encompasses 21 items, including customized and multi-functional masks, alongside other medical consumables. All of the Company’s products are sold across 34 provincial-level administrative regions in China, with 15 products also marketed in more than 30 countries globally. WORK Medical has attained numerous quality-related manufacturing certifications and has successfully registered 17 products with the U.S. Food and Drug Administration, thereby enabling their access to the U.S. market. For additional details, please visit the Company’s website: .
Forward-Looking Statements
This press release contains forward-looking statements, including those made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can often be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and similar expressions or their variations, which are used to denote forward-looking information. Any statements in this press release that do not represent historical facts should be considered forward-looking statements. Such forward-looking statements in this release are based solely on the Company’s current expectations, estimates, and projections as of this release date and are subject to various risks and uncertainties that could lead actual results to differ substantially and adversely from those expressed or implied. While the Company believes its expectations in these forward-looking statements are reasonable, it cannot guarantee their accuracy. The Company advises investors that actual outcomes may vary significantly from projected results and encourages a review of other factors that could influence its future performance, as outlined in the Company’s annual report on Form 20-F and other documents filed with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements, except where legally required.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
